SPY330.65-3.85 -1.15%
DIA276.52-2.38 -0.85%
IXIC10,793.28-117.00 -1.07%

Morgan Stanley Maintains Overweight on Ascendis Pharma, Raises Price Target to $181

Morgan Stanley maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $180 to $181.

Benzinga · 05/21/2020 11:58

Morgan Stanley maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $180 to $181.